Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 1;125(23):4148-4157.
doi: 10.1002/cncr.32361. Epub 2019 Sep 18.

Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma

Charlene M Mantia  1 , David F McDermott  1
Affiliations
Review

Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma

Charlene M Mantia et al. Cancer. .

Abstract

Advanced renal cell carcinoma has historically carried a poor prognosis with very limited treatment options. However, in recent years, the treatment landscape has changed drastically, with many new therapeutic options and improved survival for patients. Novel treatments consist of molecularly targeted agents against the vascular endothelial growth factor (VEGF) pathway as well as the immune checkpoint inhibitors, which stimulate an antitumor immune response. Recent strategy has focused on the development of combination therapy with the use of VEGF inhibitors and immune checkpoint inhibitors in the first-line setting. As more treatments are approved and the options for therapy expand further, there is a growing need for predictive biomarkers to personalize treatment choices for individual patients. Prospective clinical trials comparing the sequencing of treatments are needed to help determine the best therapeutic approach.

Keywords: combination drug therapy; immunotherapy; programmed cell death 1 receptor; renal cell carcinoma; vascular endothelial growth factors (VEGF).

PubMed Disclaimer

Conflict of interest statement

COI Disclosures: CMM has nothing to disclose. DFM discloses consulting support from BMS, Pfizer, Merck, Novartis, Exelixis, Array BioPharm, Genentech BioOncology, Alkermes Inc, Jounce Therapeutics, X4 Pharma, Peloton Therapeutics, EMD Serono, Eli Lily and Company and research support from BMS, Prometheus Laboratories, Merck, Genentech, Pfizer, Exelixis, Novartis, X4 Pharma, Alkermes Inc, Peloton.

References

    1. SEER. Cancer Stat Facts: Kidney and Renal Pelvis Cancer National Cancer Institute. https://seer.cancer.gov/statfacts/html/kidrp.html. Accessed February 22 2019.
    1. Inamura K Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int J Mol Sci 2017;18(10):2195. - PMC - PubMed
    1. Rini B, Campbell SC, Escudier B. Renal cell carcinoma. The Lancet 2009;373(9669):1119–1132. - PubMed
    1. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers 2017;3:17009. - PMC - PubMed
    1. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10(10):992–1000. - PubMed

MeSH terms

Substances